Myriad Genetics
MYGN
235 hedge funds and large institutions have $3.17B invested in Myriad Genetics in 2015 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 71 increasing their positions, 95 reducing their positions, and 40 closing their positions.
4% less capital invested
Capital invested by funds: $3.31B → $3.17B (-$145M)
7% less funds holding
Funds holding: 252 → 235 (-17)
17% less call options, than puts
Call options by funds: $18.1M | Put options by funds: $21.9M
25% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 95
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
35% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$37.8M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$33.8M |
| 3 |
SCM
Scopia Capital Management
New York
|
+$23M |
| 4 |
State Street
Boston,
Massachusetts
|
+$16.8M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KIM
Kestrel Investment Management
San Mateo,
California
|
-$21.7M |
| 2 |
RA
Royce & Associates
New York
|
-$19.8M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$17M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$16.2M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$15.7M |
MYGN Hedge Fund Activity: Q2 2015 in Review
235 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2015, worth a combined $3.17B — down 4.4% from $3.31B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of MYGN and 26 opened new positions — a net loss of 14 holders — while 95 trimmed existing stakes and 71 added.
The largest buyer was BlackRock Fund Advisors, adding an estimated $37.8M. The largest seller was Kestrel Investment Management, exiting entirely with an estimated $21.7M sold.
- 235 institutional investors held Myriad Genetics (MYGN) as of Q2 2015, down from 252 in Q1 2015.
- Funds reported $3.17B of Myriad Genetics stock for Q2 2015, down 4.4% quarter-over-quarter.
- 26 funds opened new Myriad Genetics positions in Q2 2015 and 40 closed out, a net change of -14 holders.
- The largest Myriad Genetics buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $37.8M added.
- The largest Myriad Genetics seller in Q2 2015 was Kestrel Investment Management, an estimated $21.7M sold.
Based on aggregated 13F filings for Q2 2015.